Clinical Trial Update: A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating ASP7487 (OSI-906) combined with bortezomib in relapsed multiple myeloma was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ASP7487 (OSI-906) (OSI-906)
• Bortezomib (bortezomib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-09-13